TABLE 2.

Treatment failure and non‐biopsy proven rejection rates in each tacrolimus group over the study period

	LCPT (N = 129)	PR‐Tac (N = 89)	P‐value a
Treatment failure	5 (3.9%)	8 (9.0%)	.117
Death	1 (20.0%)	3 (37.5%)	>.999
Graft failure	1 (20.0%)	3 (37.5%)	>.999
Lost to follow‐up	3 (60%)	1 (12.5%)	.217
BPAR	0 (.0%)	1 (12.5%)	>.999
Non‐biopsy‐proven rejection	2 (1.6%)	0 (.0%)	.200

Data are expressed as n (%) over the study period (Visit 1–Visit 5). The proportion of each cause of treatment failure was calculated relative to the total number of patients with treatment failure in each group.

Abbreviation: BPAR, biopsy‐proven acute rejection.

^aStatistical significance was calculated using the Fisher exact test.